期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
Global hotspots and future directions for drugs to improve the skin flap survival: A bibliometric and visualized review
1
作者 Shuangmeng Jia Jieshen Huang +5 位作者 Wuyan Lu yongen miao Kehua Huang Chenzhang Shi Shuaijun Li Jiefeng Huang 《Journal of Pharmaceutical Analysis》 SCIE CAS CSCD 2024年第7期972-982,共11页
Skin flaps are frequently employed in plastic and reconstructive surgery to address tissue defects.However,their low survival rates remain a challenge,attributed to vascular crisis and necrosis.Despite numerous studie... Skin flaps are frequently employed in plastic and reconstructive surgery to address tissue defects.However,their low survival rates remain a challenge,attributed to vascular crisis and necrosis.Despite numerous studies investigating drugs to alleviate flap necrosis,a comprehensive analysis of the research trend in this critical area is lacking.To gain a deeper understanding of the current status,research focal points,and future trends in drugs aimed at enhancing flap survival,a thorough retrospective analysis is imperative.This study aims to employ bibliometric methods to scrutinize the evolution,mechanisms,and forthcoming trends of drugs targeting flap survival improvement.Using VOSviewer software,we quantitatively and visually depict 1)annual temporal trends in the number of documents and citations;2)national/regional publications and their collaborations;3)institutional and authors’contribution;4)journal contribution and relevance;and 5)analysis of research hotspots and directions derived from keywords.Ultimately,we discussed the prospects and challenges of future advances and clinical translation of drugs designed to enhance skin flap survival.In conclusion,the field of pharmacology dedicated to improving skin flap survival is expanding,and this study aims to offer a fresh perspective to promote the advancement and clinical application of such drugs. 展开更多
关键词 Skin flap Drug therapy Bibliometric analysis Global trends
在线阅读 下载PDF
罕见EGFR L833V/H835L复合突变的肺腺癌患者1例及文献回顾
2
作者 缪永恩 汪瑜堃 +4 位作者 李萍 谈敏 文婷婷 王昌惠 谢栓栓 《中国肺癌杂志》 CAS CSCD 北大核心 2023年第10期795-800,共6页
表皮生长因子受体(epidermal growth factor receptor,EGFR)突变是非小细胞肺癌(non-small cell lung cancer,NSCLC)发生发展过程中最常见的驱动基因,其中18-21号外显子的突变常见,尤其是19号外显子的缺失和21号外显子L858R点突变最为常... 表皮生长因子受体(epidermal growth factor receptor,EGFR)突变是非小细胞肺癌(non-small cell lung cancer,NSCLC)发生发展过程中最常见的驱动基因,其中18-21号外显子的突变常见,尤其是19号外显子的缺失和21号外显子L858R点突变最为常见,但是EGFR L833V/H835L罕见基因复合突变的发生率非常低,患者数量很少,相关临床数据和治疗方法的证据也不足。部分EGFR-酪氨酸激酶抑制剂(EGFR-tyrosine kinase inhibitors,EGFR-TKIs)在治疗伴有罕见基因突变的肺癌患者方面同样具有良好疗效。本文报道了1例携带EGFR L833V/H835L罕见基因复合突变的NSCLC患者,在给予阿法替尼治疗5个月后,计算机断层扫描(computed tomography,CT)显示肺部病灶缩小,患者对阿法替尼联合安罗替尼治疗反应良好。同时,我们还对以往报道的EGFR L833V/H835L罕见基因复合突变的NSCLC患者进行了整理,总结了该类患者的特点及应用不同种类EGFR-TKIs治疗的效果。 展开更多
关键词 肺肿瘤 表皮生长因子受体 复合突变 L833V/H835L 阿法替尼
在线阅读 下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部